Abstract
Pixantrone was shown to reduce the severity of clinical manifestation in experimental myasthenia gravis. In the present work we further studied its therapeutic effect. Our results demonstrate that a single administration suppressed AChR-specific immune-responses in primed rats. However, clinical symptoms could be improved only by repeated drug administrations (q7dx6 protocol-8.12. mg/kg); this treatment allowed stable serum drug levels for at least 7. days, as assessed by a functional T-cell bioassay. Pixantrone exerted strong in vitro inhibitory effect only on proliferating T-cells without impairing dendritic cell differentiation and B-cell viability. Our data further demonstrate that Pixantrone is a promising immunosuppressant drug that should be investigated in myasthenia gravis.
Original language | English |
---|---|
Pages (from-to) | 41-50 |
Number of pages | 10 |
Journal | Journal of Neuroimmunology |
Volume | 258 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - 2013 |
Keywords
- Acetylcholine receptor (AChR)
- Experimental autoimmune myasthenia gravis (EAMG)
- Immunomodulation
- Pixantrone
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology